Cargando…
Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia
Kuo and colleagues(1) evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia. The high rate of hemoglobin response and good tolerability encourages further development in thalassemia.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589095/ https://www.ncbi.nlm.nih.gov/pubmed/36260990 http://dx.doi.org/10.1016/j.xcrm.2022.100790 |